BioVaxys Bolsters Vaccine Development with Expert Advisor
Company Announcements

BioVaxys Bolsters Vaccine Development with Expert Advisor

Story Highlights

BioVaxys Technology (TSE:BIOV) has released an update.

BioVaxys Technology Corp. has announced the engagement of Dr. Rajkannan Rajagopalan as an advisor to enhance the development and production of the company’s innovative DPX™ vaccine formulations. Dr. Rajagopalan’s extensive experience in nanoparticle formulation for various diseases brings a wealth of knowledge to the company’s vaccine programs, including a peanut allergy vaccine and ongoing oncology and infectious disease studies. His expertise is expected to bolster BioVaxys’s capabilities in creating a thermostable vaccine platform and assisting in the establishment of a non-GLP clinical supply facility.

For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskBioVaxys Joins US Vaccine Development Consortium
TipRanks Canadian Auto-Generated NewsdeskBioVaxys Advances in Drug Delivery Market
TipRanks Canadian Auto-Generated NewsdeskBioVaxys to Present at Emerging Growth Conference
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App